The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Michael Igor Huttner - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Fantastic. I've got a fishing question. I hope you like it. The [SCOR] today, another [tension transitioned] gave a figure for their IFRS 17 balance sheet,
including contracted service margin. I think the figure is EUR 9 billion. And I just wondered, what is your figure (inaudible) I'm sure you have it and
I wondered -- I'm sure it could be good opportunity to start discussing IFRS 17. It's not that far away.
My second question is on inflation and pricing. You made lots of different comments on inflation and pricing. Some bits were good. Some bits you
didn't talk about, so they're presumably not good. I just wondered if you could kind of go back over it and give us a little bit more clarity? At the
moment, I see that AXA XL is good. I'm not sure if the rest of commercial lines is good or not, not clear for me. So maybe I'm not clear. And Personal
lines, it sounds like there's a big lag, but maybe you can explain what's happening? That would be really, really helpful.
And then the final one is a really small one. What is solvency expect?
Question: Michael Igor Huttner - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Solvency today, as of now.
Question: Michael Igor Huttner - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Can I just interrupt?
Question: Michael Igor Huttner - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: I think you might think again. If [SCOR] can do it, there's no reason AXA can't do it. And I imagine a lot of investors will be asking that question. So
my feeling is you should accelerate that. Investors will welcome it. And if you don't, they might feel a little bit (inaudible).
|